0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

1
Articles   |    
Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder
Aybala Saricicek, M.D.; Irina Esterlis, Ph.D.; Kathleen H. Maloney, B.A.; Yann S. Mineur, Ph.D.; Barbara M. Ruf, B.A.; Anjana Muralidharan, B.A.; Jason I. Chen, B.A.; Kelly P. Cosgrove, Ph.D.; Rebecca Kerestes, Ph.D.; Subroto Ghose, M.D., Ph.D.; Carol A. Tamminga, M.D.; Brian Pittman, M.S.; Frederic Bois, Ph.D.; Gilles Tamagnan, Ph.D.; John Seibyl, M.D.; Marina R. Picciotto, Ph.D.; Julie K. Staley, Ph.D.; Zubin Bhagwagar, M.D., Ph.D., M.R.C.Psych.
Am J Psychiatry 2012;169:851-859. doi:10.1176/appi.ajp.2012.11101546
View Author and Article Information
From the Department of Psychiatry, Yale University, New Haven, Conn.; the Neuroscience Group, Bristol-Myers Squibb, Wallingford, Conn.; the Institute for Neurodegenerative Disorders, New Haven, Conn.; and the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas.

Received Oct. 20, 2011; revisions received Jan. 7 and April 3, 2012; accepted April 9, 2012.

Dr. Seibyl reports being a consultant for Bayer Healthcare and GE Healthcare and holding equity in Molecular Neuroimaging. Dr. Bhagwagar is a full-time employee of Bristol-Myers Squibb while retaining a faculty position at Yale University. Disclosures for Dr. Tamminga, as a Deputy Editor of the American Journal of Psychiatry, were published in the January issue. The other authors report no financial relationships with commercial interests.

Dr. Staley died in July 2009.

Supported by the Clinical Neuroscience Research Unit at the Connecticut Mental Health Center and the Connecticut Department of Mental Health and Addictions Services, by NIMH research grants MH-077681 (Dr. Picciotto) and MH-077914 (Dr. Bhagwagar), by the Brain & Behavior Research Foundation (Dr. Bhagwagar), by the Freedman Fellowship (Dr. Saricicek), and by Clinical and Translational Science Award grant UL1 RR-024139 from the NIH National Center for Research Resources to Yale University (Dr. Bhagwagar).

Address correspondence to Dr. Saricicek (aybala.saricicek@yahoo.com) or Dr. Bhagwagar (zubin.bhagwagar@bms.com).

Copyright © American Psychiatric Association

Received October 20, 2011; Revised January 7, 2012; Revised April 3, 2012; Accepted April 9, 2012.

Abstract

Background:  Modulation of nicotinic acetylcholine receptors (nAChRs), specifically those containing the β2 subunit, may be effective in treating patients with major depressive disorder. Using [123I]5-I-A-85380 single photon emission computed tomography (SPECT), the authors studied the availability of β2-subunit-containing nAChRs (β2*-nAChRs) in depressed patients. To understand its molecular basis, the authors also studied β2*-nAChR binding in postmortem brain samples from depressed subjects.

Method:  The participants were 23 medication-free, nonsmoking subjects with familial, early-onset depression (eight acutely ill and 15 recovered) and 23 age- and gender-matched nonsmoking comparison subjects. Each received one [123I]5-I-A-85380 SPECT scan and an MRI scan. The availability of β2*-nAChRs was quantified as VT/fP. Postmortem analysis of β2*-nAChR binding was conducted with [123I]5-I-A-85380 on prefrontal cortex samples from 14 depressed subjects and 14 age-matched comparison subjects.

Results:  The β2*-nAChR availability in both the acutely ill and recovered depressed subjects was significantly lower across all brain regions than in the respective comparison subjects, and it was lower in the acutely ill subjects than in those who were recovered. In the depressed patients, β2*-nAChR availability was significantly correlated with lifetime number of depressive episodes, trauma score, and anxiety score. There were no differences in β2*-nAChR number between groups in the postmortem study.

Conclusions:  Depressed patients have lower β2*-nAChR availability than do healthy subjects. The difference between β2*-nAChR availability in vivo and in post-mortem samples may be analogous to data with dopaminergic PET ligands and dopamine receptor availability; lower receptor availability for the SPECT ligand could be caused by greater endogenous acetylcholine.

Abstract Teaser
Figures in this Article

Converging lines of evidence suggest that the cholinergic system may be a target for the development of novel molecular approaches for the treatment of depression (1). First, cholinergic hyperactivity plays a role in the pathophysiology of depression (24) and can exacerbate depression-like symptoms in patients and comparison subjects (46). Second, tobacco dependence is highly prevalent in patients with major depressive disorder (7), and depressed patients have a high prevalence of smokers (810). Population-based studies show that smokers are twice as likely as nonsmokers to have a lifetime history of major depression (1113). Furthermore, nicotine binds to neuronal nicotinic acetylcholine receptors (nAChRs), and partial agonists and antagonists of nAChRs, including nicotine (14), mecamylamine and dihydro-β-erythroidine (15), cytisine (16), and varenicline (17), have antidepressant-like effects in preclinical studies. However, mice lacking the β2 nAChR subunit are insensitive to the antidepressant-like effects of mecamylamine (15) and amitriptyline (18). This suggests that β2-subunit-containing (β2*) nAChRs may be important for the antidepressant-like effect in preclinical models of depression. In addition to nicotine (19, 20), nAChR modulators have been used successfully in clinical trials. Mecamylamine (21), the S-enantiomer of mecamylamine (http://clinicaltrials.gov/ct2/show/NCT00593879), and varenicline (22) have been shown to have antidepressant effects in depression.

The development and use of [123I]5-I-A-85380 ([123I]-5-iodo-3-[2(S)-2-azetidinylmethoxy] pyridine) as a radioligand in single photon emission computed tomography (SPECT) to quantify β2*-nAChRs in vivo in the human brain now allow unparalleled access to this system in vivo (2325). The objective of our study was to determine whether there is a core dysfunction in the β2*-nAChR system in depression, as assessed by using SPECT and the selective β2*-nAChR radioligand [123I]5-I-A-85380. We chose to study subjects who were fully recovered from major depression in order to avoid the confounding effects of acute illness or antidepressant treatment (26). We hypothesized that patients with major depressive disorder would have lower β2*-nAChR availability than healthy comparison subjects.

As in radioligand-based studies of dopamine in humans, it is critically important to note that changes in receptor availability in vivo could be due to a change in receptor number or a change in receptor occupancy. It has been shown previously in nonhuman primates that elevated acetylcholine levels induced by a high dose of intravenous physostigmine, an acetylcholinesterase inhibitor, can compete effectively in vivo with [123I]5-I-A-85380 binding at β2*-nAChRs (27). Therefore, lower binding of [123I]5-I-A-85380 to the β2*-nAChR could reflect one of two processes: an actual, absolute change in the number of receptors or a change in synaptic acetylcholine levels, such that an increased amount of acetylcholine would prevent the radioligand from binding to the receptor, resulting in low binding of the radioligand.

We also quantified β2*-nAChR availability in postmortem samples of brains from depressed patients and healthy comparison subjects. In the absence of endogenous acetylcholine, β2*-nAChR availability in the postmortem human samples would help interpret the precise mechanism of potential binding abnormalities observed with [123I]5-I-A-85380 in humans.

+

SPECT Study

+

Participants.

Each prospective subject had an interview with an experienced psychiatrist, who elicited a complete psychiatric and medical history and conducted a Structured Clinical Interview for DSM-IV Disorders (SCID-I) (28), standardized psychiatric assessments, and a physical examination. Routine blood tests, a pregnancy test, urine toxicology, and ECG were also performed. In addition, the participants were given the Beck Depression Inventory (BDI) (29), the Center for Epidemiologic Studies Depression Scale (CES-D Scale) (30), the Spielberger State-Trait Anxiety Inventory (31), the NEO Personality Inventory–Revised (32), the Childhood Trauma Questionnaire (33), and the 21-item Hamilton Depression Rating Scale item (HAM-D) (34).

The study participants were 23 nonsmoking, medication-free subjects with recurrent major depressive disorder and 23 age- and gender-matched healthy comparison subjects. Eight of the subjects with major depression were acutely ill, and 15 were fully recovered. Subjects with any other significant axis I diagnosis were excluded from the study, and only those with a primary diagnosis of major depressive disorder were included. In accordance with previous studies of depressed subjects (3537), all of those in the current study had 1) an onset of the first major depressive episode before age 25 years, 2) a lifetime history of at least two major depressive episodes, and 3) at least one first-degree relative with a reported history of major depressive disorder or an axis I disorder.

The depressed subjects had been medication-free for at least 3 months, and the acutely ill subjects scored above 16 on the HAM-D. Subjects were classified as recovered from major depression on the basis of four criteria: self-reported euthymia for more than 4 months following the last episode of major depression, clinician-rated euthymia for more than 4 months according to a clinical interview, absence of criteria for a major depressive episode for more than 4 months as judged with the SCID-I, and a HAM-D score of less than 8. Comparison nonsmoking subjects were included in the study only if they had no lifetime history or family history (in a first-degree relative) of any axis I or axis II disorder as judged with the SCID-I.

None of the subjects recruited had smoked for at least 6 months, and 14 of the depressed subjects (six acutely ill and eight recovered) reported no lifetime history of smoking. Nonsmoking status was confirmed by a plasma cotinine level less than 15 ng/ml, a urine cotinine level less than 100 ng/ml (confirmed by using a dipstick urine test on the day of the scan), and exhaled carbon monoxide level less than 11 ppm on the day of intake and on the day of the scan. Subjects were excluded if they had a positive pregnancy test on the day of the SPECT scan or prior radiation exposure within the past year such that participation in this study would place them over the U.S. Food and Drug Administration (FDA) limit for annual radiation exposure.

This study was approved by the Yale University School of Medicine Human Investigation Committee and the Radiation Safety Committee. After complete description of the study to the subjects, written informed consent was obtained. The use of the radiotracer [123I]5-I-A-85380 was approved by the FDA.

+

Imaging.

Each subject had one [123I]5-I-A-85380 SPECT scan and one magnetic resonance imaging (MRI) scan. MRI was performed on a Signa 1.5-T system (General Electric, Milwaukee, Wis.) as described previously (38). SPECT imaging was conducted as described previously (39). In brief, [123I]5-I-A-85380 was administered by using a bolus plus constant infusion at a ratio of 7.0 hours (i.e., with a bolus worth 7 hours of infusion) for 8 hours. There were no significant differences in the total injected dose, bolus dose, infusion dose, or bolus-to-infusion ratio between the depressed and comparison groups (Table 1). Three 30-minute emission scans and one 15-minute simultaneous transmission and emission protocol (STEP) scan were obtained between 6 and 8 hours of the infusion on a Picker PRISM 3000 XP SPECT camera (Picker, Cleveland). Plasma samples were collected in the middle of the second scan to quantify the total amount of parent tracer and the free fraction (fp) in plasma (40) and to correct for individual differences in metabolism and protein binding of [123I]5-I-A-85380 (41). A 57Co-distributed source was measured with each experiment to control for day-to-day variation in camera sensitivity.

 
Anchor for Jump
TABLE 1.

Radiochemical Measures for [123I]5-I-A-85380 SPECT Imaging of Acutely Ill and Recovered Patients With Major Depressive Disorder and Matched Healthy Comparison Subjectsa

Table Footer Note

a Matched on age and gender.

Table Footer Note

b Hours of infusion equivalent to bolus dose.

+

Image analysis and outcome measures.

SPECT emission images were analyzed as described previously (25). Specifically, SPECT emission images were reconstructed by using a filtered-back projection algorithm with a ramp filter on a 128×128 matrix to obtain 50 slices with a pixel size of 2.06×2.06×3.56 mm in the x, y, and z axes. A three-dimensional Butterworth filter (order 10, cutoff frequency 0.24 cycle/pixel) was applied post hoc. A coregistered magnetic resonance (MR) image was used to guide the placement of standard two-dimensional region-of-interest templates by means of MEDx software (Medical Numerics, Germantown, Md.). A three-dimensional volume of interest was generated for each region and transferred to the coregistered SPECT image to determine regional radioactive densities. The chosen regions were those known to contain β2*-nAChRs and included the frontal, parietal, anterior cingulate, temporal, and occipital regions, the thalamus, the striatum (an average of caudate and putamen), the hippocampus, the amygdala, the brainstem, and the cerebellum. Regional [123I]5-I-A-85380 uptake was determined by VT/fp, where VT is the total volume of distribution and fp is the free plasma fraction. Each case was analyzed by two raters, and the mean of the two raters' values was used. Interrater variability for VT/fp was less than 10% across all regions and was computed as the percentage difference between the two raters by means of the following equation: [(VT/fp1 / VT/fp2)–1]×100=% difference.

+

Voxel-Based Morphometric Analysis

In order to study any volumetric differences, as previously reported in patients with major depression (42, 43), a voxel-based morphometric analysis of the data was performed with SPM5 (Wellcome Trust Centre for Neuroimaging, London). A detailed description of the steps involved in processing data for voxel-based morphometry is available in the SPM5 manual (http://www.fil.ion.ucl.ac.uk/spm/). Before preprocessing, the images were checked for movement artifacts and the origin of each image was set at the anterior commissure. The images were segmented, normalized, and smoothed simultaneously by means of a unified segmentation algorithm (44). In contrast to optimized voxel-based morphometry, which was used in SPM2 and in which these steps were completed sequentially, this study used the unified segmentation algorithm in SPM5 to simultaneously calculate image registration, tissue classification, and bias correction by using our participants' structural MR images combined with the tissue probability maps provided in this version of SPM. Structural MR images were segmented into gray matter, white matter, and CSF. The segmented and modulated normalized images were smoothed with an 8-mm full-width-half-maximum filter. A two-sample t test was then used to delineate any significant differences in gray matter volume between the depressed and healthy comparison groups (N=23 each), between the recovered depressed and matched comparison groups (N=15 each), and between the acutely depressed and matched comparison groups (N=8 each) separately. Given the small number of subjects and the preliminary nature of this analysis, a threshold of p<0.05, uncorrected, was used to view the results.

+

Postmortem Study

Human brain specimens from the prefrontal cortex of 14 depressed subjects and 14 age-matched comparison subjects were obtained from the Dallas Brain Collection (45). Methods are described in the data supplement accompanying the online version of this article.

+

Statistical Analysis

All data were analyzed by using SAS version 9.1 (SAS Institute, Cary, N.C.). Before analysis, the data were examined descriptively and tested for normality by using normal probability plots and Kolmogorov test statistics. All data were approximately normal. Receptor binding data were analyzed by means of linear mixed models. These models included region as a within-subjects factor, diagnostic group (acutely depressed, recovered depressed, and respective comparison subjects) as a between-subjects factor, and the interaction between group and region. On the basis of the Bayesian information criterion, the best-fitting variance-covariance structure was compound symmetry with heterogeneous variance—i.e., a constant correlation between regions and region-specific variances are estimated. Significant interactions were explained by appropriate post hoc tests and graphical displays. Post hoc tests were adjusted for the 11 regional comparisons by using the Bonferroni correction (i.e., a two-sided alpha of 0.0045 was used as the threshold). An omnibus model including the four diagnostic groups was first developed. After a significant group-by-region interaction was confirmed, separate models were developed for 1) all depressed patients versus all comparison subjects, 2) acutely ill patients versus respective comparison subjects, 3) recovered patients versus respective comparison subjects, and 4) acutely ill versus recovered depressed patients. Inclusion of age and gender as covariates did not alter the results, and they were therefore dropped from the analysis. Potential associations between binding potential and crucial clinical variables of interest were assessed by using correlation analysis. In order to control for multiple correlations, the correlations of clinical and personality variables with binding data were reported only where significant correlations were observed consistently in a region. Postmortem data were analyzed by using analysis of variance (ANOVA), and correlations were analyzed by using appropriate correlation coefficients. For these data, each cell was an average of three measurements performed for each brain region for each patient. The data were then analyzed by ANOVA with group (comparison or depressed) as a between-subjects factor and brain region (gray or white matter) as a within-subjects factor. Alpha was set at 5%.

+

SPECT Study

+

Subject characteristics.

Clinical and demographic characteristics of the participants in each group are shown in Table 2; the groups were well matched on most variables studied, although there were significant differences in ethnicity and lifetime smoking history among the groups. Consistent with the acute nature of their illness, the subjects in the acute depression group had significantly higher scores on the CES-D scale, the BDI, the NEO Personality Inventory neuroticism subscale, the Childhood Trauma Questionnaire total scale and physical neglect subscale, and the Spielberger State-Trait Anxiety Inventory and significantly lower scores on the NEO Personality Inventory conscientiousness subscale than the subjects recovered from major depression.

 
Anchor for Jump
TABLE 2.

Demographic and Clinical Characteristics of Acutely Ill and Recovered Patients With Major Depressive Disorder and Matched Healthy Comparison Subjectsa

Table Footer Note

a Matched on age and gender.

Table Footer Note

b Subjects with episodic illness were included.

Table Footer Note

c Scores of the comparison subjects for the acutely ill group are based on only two subjects. Scores of the comparison subjects for the recovered group are based on six subjects.

Table Footer Note

d Scores are based on five acutely ill patients and two of their respective comparison subjects and on 12 recovered patients and six of their respective comparison subjects.

+

β2*-nAChR availability in major depressive disorder.

The radiochemical blood measures are shown in Table 1. Figure 1 presents β2*-nAChR availability by region. The results of the omnibus model including all four diagnostic groups revealed a significant effect of group (F=8.7, df=3, 42, p<0.0001) and a significant group-by-region interaction (F=1.8, df=30, 420, p=0.006). Given the significant interaction, we chose to disentangle the group-by-region differences by developing independent models including two groups at a time.

 
Anchor for JumpAnchor for Jump
FIGURE 1.

Regional Availability of β2*-Nicotinic Acetylcholinergic Receptors (β2*-nAChRs) in Acutely Ill and Recovered Patients With Major Depressive Disorder and Matched Healthy Comparison Subjectsa

a Matched on age and gender.

b Determined by VT/fp, where VT is the volume of distribution and fp is the free plasma fraction. Values are means and standard deviations.

In the comparison of acutely depressed patients and their comparison subjects, there was a significant main effect of group (F=15.8, df=1, 14, p=0.002) and a significant interaction between group and region (F=2.5, df=10, 140, p=0.008). Post hoc comparisons revealed lower β2*-nAChR availability in the acutely ill depressed subjects than in the healthy comparison subjects in nine of the 11 regions of interest examined (for all regions except the hippocampus and amygdala, adjusted p<0.007).

In the comparison of the recovered depressed patients and their matched comparison subjects, there was also a significant group effect (F=7.9, df=1, 28, p=0.009) and group-by-region interaction (F=2.0, df=10, 280, p=0.03). Post hoc comparisons showed lower β2*-nAChR availability among patients than among comparison subjects in the frontal cortex (adjusted p=0.03), anterior cingulate (adjusted p=0.04), and thalamus (adjusted p=0.008).

When we compared the acutely ill and recovered depression patients, we found a significant overall group effect (F=10.0, df=1, 21, p=0.005), with lower overall β2*-nAChR availability in the acutely depressed patients than in those who were recovered. However, the interaction between group and region was not significant (F=1.3, df=10, 210, p=0.21).

+

Correlation of β2*-nAChR availability with clinical features.

The analysis of lifetime number of episodes included 19 patients (four acutely ill, 15 recovered). There was a significant positive correlation between lifetime number of episodes and β2*-nAChR availability in the temporal cortex (r=0.46, p<0.05), occipital cortex (r=0.48, p=0.04), and striatum (r=0.49, p=0.04). This was also observed in the recovered group alone (N=15) in the temporal cortex (r=0.54, p=0.04), occipital cortex (r=0.56, p=0.03), thalamus (r=0.54, p=0.04), and striatum (r=0.58, p=0.03).

In the patients with acute depression but not the recovered group, the scores on the total Childhood Trauma Questionnaire and its emotional abuse subscale were negatively correlated with receptor availability in all regions of interest studied except the amygdala. The score on the trait subscale of the Spielberger State-Trait Anxiety Inventory was negatively correlated with receptor availability in the anterior cingulate (r=–0.65, p=0.03), temporal (r=–0.64, p=0.03), and occipital (r=–0.65, p=0.03) regions and showed a nearly significant correlation in the striatum (r=–0.51, p=0.09) in the recovered group but not in the acutely ill patients. The score on the NEO Personality Inventory conscientiousness subscale was significantly correlated with receptor availability in all regions of interest studied except the amygdala and brainstem (which showed a nearly significant correlation) in the acutely ill group but not the recovered group.

The relationship between a history of past cigarette smoking and β2*-nAChR availability could not be studied because of the small and unbalanced number of subjects with a past history of cigarette smoking.

+

Voxel-Based Morphometric Analysis

An SPM analysis of brain volumes of all depressed patients in relation to all comparison subjects showed no significant differences in volume, even at the relatively generous threshold used in the analysis. Similarly, there were no significant differences in volume between the acutely ill depressed subjects and their respective comparison subjects, between the recovered depressed subjects and their respective comparison subjects, or between the acutely ill and recovered depressed subjects.

+

Postmortem Study

Demographic data for the patients with a diagnosis of major depressive disorder and the matched comparison subjects and the results of [125I]5-I-A-85380 equilibrium binding in postmortem brain tissue are provided in the data supplement accompanying the online version of this article. There were no statistically significant differences in β2*-nAChR number between the depressed patients and the healthy comparison subjects. Both the main effect of group (F=0.46, df=1, 23, p=0.52) and the interaction of region and group (F=0.23, df=1, 46, p=0.78) were nonsignificant.

This multimodal analysis of β2*-nAChR availability shows that major depressive disorder is associated with significant dysfunction in the cholinergic system. From the in vivo data, we observed that acutely ill and recovered patients with major depression had significantly lower β2*-nAChR availability than age- and gender-matched comparison subjects. Crucially, there were no differences in β2*-nAChR number between the postmortem samples of depressed and comparison subjects under conditions that washed out any endogenous bound acetylcholine. This suggests that the lower β2*-nAChR availability in vivo is likely better explained by high levels of extracellular acetylcholine in patients with major depression than by a low total number of receptors. This would be consistent with the cholinergic hypothesis of depression (4). Finally, we found that the lower β2*-nAChR availability in depressed patients had functional effects in that it was related to critical personality measures.

+

Use of [123I]5-I-A-85380 to Quantify β2*-nAChR Availability

Our data demonstrate a persistent enduring deficit in cortical and subcortical β2*-nAChR availability in subjects with major depressive disorder. As the acutely ill patients had significantly lower β2*-nAChR availability than the recovered subjects in most regions, it is possible that acetylcholine levels recover somewhat in patients with remitted depression. The continued significantly lower β2*-nAChR availability in fully recovered, euthymic medication-free subjects with depression suggests that the changes in depression are not an epiphenomenon of treatment or illness but may be associated with trait vulnerability to depression, as demonstrated by us previously for other targets (26, 46, 47). nAChRs have a ubiquitous role in the modulation of multiple neurotransmitter systems considered crucial in the pathophysiology of depression, such as serotonin, noradrenaline, glutamate, and GABA (48), and the observed dysfunction may reflect a cause or effect of dysfunction in these other systems. Finally, there were no differences in brain volume between the patients and comparison subjects, suggesting that brain atrophy could not account for differences in receptor availability in this study group.

+

Postmortem Studies

As described in the preceding, the lower binding of the SPECT radioligand [123I]5-I-A-85380 to β2*-nAChRs could reflect an actual, absolute abnormality in the number of receptors or it could reflect a difference in synaptic acetylcholine levels, with a greater amount of acetylcholine preventing the radioligand from binding to the receptor (27). Consistent with the latter possibility, the postmortem samples showed no difference in receptor number between the depressed patients and either comparison group. These results, together with the nonhuman primate study (27), suggest that when β2*-nAChR availability is measured in the absence of bound endogenous acetylcholine, there is no evidence of an abnormality in receptor number.

+

Functional Consequences of Lower β2*-nAChR Availability

We observed a significant positive correlation between the number of depressive episodes and β2*-nAChR availability in the combined depressed group and in the recovered patients. If we assume that the lower β2*-nAChR availability represents higher extracellular acetylcholine levels, the correlation implies that the greater the number of episodes, the greater the amount of extracellular acetylcholine. Studies suggest that tobacco smokers have higher β2*-nAChR availability than do nonsmokers in nonpsychiatric populations (39) and that it normalizes after 6–12 weeks of abstinence (49). However, given the small and unbalanced number of subjects with a past history of cigarette smoking, we were not able to determine the effect of this variable on β2*-nAChR availability. Finally, the association between childhood trauma and β2*-nAChR availability replicates the relationship between trauma and major depressive disorder that has been observed in previous studies (50).

+

Limitations

Notwithstanding the robust statistical significance of the SPECT binding results, the study group was relatively small and composed nearly entirely of subjects without a past history of cigarette smoking; only 11 of the 46 subjects studied had a past history of cigarette smoking. Future studies need to be performed to examine the relationship between past cigarette smoking and β2*-nAChR availability. The nature and logistics of using a SPECT radioligand, the absence of a quantifiable reference region and input function, and the absence of a measurement of nondisplaceable binding in patients with major depressive disorder are issues that are beyond the scope of this article but have been addressed in detail elsewhere (25, 27, 51). While the amygdala is a crucial structure in the pathophysiology of depression, SPECT has poor resolution for small brain regions and the findings for the amygdala should be interpreted with caution. A PET study needs to be performed to confirm these results. Although past smoking status is a critical issue, it was not possible to analyze this effect adequately given the small and unequal number of subjects who have smoked in the past. The use of a population exclusively composed of lifetime nonsmokers limits generalizability; however, it is essential to interpretation of the results and should be examined in future studies.

+

Conclusions

Patients with major depressive disorder show lower β2*-nAChR availability that persists beyond the cessation of treatment and into full recovery. Further studies are needed to clarify the molecular underpinnings of this low receptor availability. A similar study using a SPECT ligand specific to β4-containing nAChRs seems warranted because of the high density of these receptors in the habenula complex, a region increasingly implicated in depressed mood states (52).

Shytle  RD;  Silver  AA;  Lukas  RJ;  Newman  MB;  Sheehan  DV;  Sanberg  PR:  Nicotinic acetylcholine receptors as targets for antidepressants.  Mol Psychiatry 2002; 7:525–535
[CrossRef] | [PubMed]
 
Owens  MJ;  Overstreet  DH;  Knight  DL;  Rezvani  AH;  Ritchie  JC;  Bissette  G;  Janowsky  DS;  Nemeroff  CB:  Alterations in the hypothalamic-pituitary-adrenal axis in a proposed animal model of depression with genetic muscarinic supersensitivity.  Neuropsychopharmacology 1991; 4:87–93
[PubMed]
 
Dilsaver  SC:  Pathophysiology of “cholinoceptor supersensitivity” in affective disorders.  Biol Psychiatry 1986; 21:813–829
[CrossRef] | [PubMed]
 
Janowsky  DS;  el-Yousef  MK;  Davis  JM;  Sekerke  HJ:  A cholinergic-adrenergic hypothesis of mania and depression.  Lancet 1972; 2:632–635
[CrossRef] | [PubMed]
 
Risch  SC;  Cohen  RM;  Janowsky  DS;  Kalin  NH;  Murphy  DL:  Mood and behavioral effects of physostigmine on humans are accompanied by elevations in plasma beta-endorphin and cortisol.  Science 1980; 209:1545–1546
[CrossRef] | [PubMed]
 
Janowsky  DS;  Overstreet  DH:  Cholinergic dysfunction in depression.  Pharmacol Toxicol 1990; 66(suppl 3):100–111
[CrossRef] | [PubMed]
 
Zimmerman  M;  Chelminski  I;  McDermut  W:  Major depressive disorder and axis I diagnostic comorbidity.  J Clin Psychiatry 2002; 63:187–193
[CrossRef] | [PubMed]
 
Hughes  JR;  Hatsukami  DK;  Mitchell  JE;  Dahlgren  LA:  Prevalence of smoking among psychiatric outpatients.  Am J Psychiatry 1986; 143:993–997
[PubMed]
 
Poirier  MF;  Canceil  O;  Bayle  F;  Millet  B;  Bourdel  MC;  Moatti  C;  Olie  JP;  Attar-Levy  D:  Prevalence of smoking in psychiatric patients.  Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:529–537
[CrossRef] | [PubMed]
 
Glassman  AH:  Cigarette smoking: implications for psychiatric illness.  Am J Psychiatry 1993; 150:546–553
[PubMed]
 
Breslau  N;  Kilbey  MM;  Andreski  P:  Nicotine dependence and major depression: new evidence from a prospective investigation.  Arch Gen Psychiatry 1993; 50:31–35
[CrossRef] | [PubMed]
 
Quattrocki  E;  Baird  A;  Yurgelun-Todd  D:  Biological aspects of the link between smoking and depression.  Harv Rev Psychiatry 2000; 8:99–110
[PubMed]
 
Grant  BF;  Hasin  DS;  Chou  SP;  Stinson  FS;  Dawson  DA:  Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions.  Arch Gen Psychiatry 2004; 61:1107–1115
[CrossRef] | [PubMed]
 
Tizabi  Y;  Overstreet  DH;  Rezvani  AH;  Louis  VA;  Clark  E  Jr;  Janowsky  DS;  Kling  MA:  Antidepressant effects of nicotine in an animal model of depression.  Psychopharmacology (Berl) 1999; 142:193–199
[CrossRef] | [PubMed]
 
Rabenstein  RL;  Caldarone  BJ;  Picciotto  MR:  The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice.  Psychopharmacology (Berl) 2006; 189:395–401
[CrossRef] | [PubMed]
 
Mineur  YS;  Somenzi  O;  Picciotto  MR:  Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice.  Neuropharmacology 2007; 52:1256–1262
[CrossRef] | [PubMed]
 
Rollema  H;  Guanowsky  V;  Mineur  YS;  Shrikhande  A;  Coe  JW;  Seymour  PA;  Picciotto  MR:  Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect.  Eur J Pharmacol 2009; 605:114–116
[CrossRef] | [PubMed]
 
Caldarone  BJ;  Harrist  A;  Cleary  MA;  Beech  RD;  King  SL;  Picciotto  MR:  High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation.  Biol Psychiatry 2004; 56:657–664
[CrossRef] | [PubMed]
 
Salin-Pascual  RJ;  de la Fuente  JR;  Galicia-Polo  L;  Drucker-Colin  R:  Effects of transdermal nicotine on mood and sleep in nonsmoking major depressed patients.  Psychopharmacology (Berl) 1995; 121:476–479
[CrossRef] | [PubMed]
 
McClernon  FJ;  Hiott  FB;  Westman  EC;  Rose  JE;  Levin  ED:  Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial.  Psychopharmacology (Berl) 2006; 189:125–133
[CrossRef] | [PubMed]
 
George  TP;  Sacco  KA;  Vessicchio  JC;  Weinberger  AH;  Shytle  RD:  Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study.  J Clin Psychopharmacol 2008; 28:340–344
[CrossRef] | [PubMed]
 
Patterson  F;  Jepson  C;  Strasser  AA;  Loughead  J;  Perkins  KA;  Gur  RC;  Frey  JM;  Siegel  S;  Lerman  C:  Varenicline improves mood and cognition during smoking abstinence.  Biol Psychiatry 2009; 65:144–149
[CrossRef] | [PubMed]
 
Musachio  JL;  Villemagne  VL;  Scheffel  UA;  Dannals  RF;  Dogan  AS;  Yokoi  F;  Wong  DF:  Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon.  Nucl Med Biol 1999; 26:201–207
[CrossRef] | [PubMed]
 
Fujita  M;  Tamagnan  G;  Zoghbi  SS;  Al-Tikriti  MS;  Baldwin  RM;  Seibyl  JP;  Innis  RB:  Measurement of alpha4beta2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT.  J Nucl Med 2000; 41:1552–1560
[PubMed]
 
Staley  JK;  van Dyck  CH;  Weinzimmer  D;  Brenner  E;  Baldwin  RM;  Tamagnan  GD;  Riccardi  P;  Mitsis  E;  Seibyl  JP:  123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility.  J Nucl Med 2005; 46:1466–1472
[PubMed]
 
Bhagwagar  Z;  Cowen  PJ:  'It's not over when it's over': persistent neurobiological abnormalities in recovered depressed patients.  Psychol Med 2008; 38:307–313
[CrossRef] | [PubMed]
 
Fujita  M;  Al-Tikriti  MS;  Tamagnan  G;  Zoghbi  SS;  Bozkurt  A;  Baldwin  RM;  Innis  RB:  Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5-I-A-85380.  Synapse 2003; 48:116–122
[CrossRef] | [PubMed]
 
First  MB;  Spitzer  RL;  Gibbon  M;  Williams  JBW:  Structured Clinical Interview for DSM-IV Axis I Disorders—Clinician Version (SCID-CV) .  Washington, DC,  American Psychiatric Press, 1997
 
Beck  AT;  Steer  RA;  Brown  GK:  Beck Depression Inventory, 2nd ed, Manual .  San Antonio, Tex,  Psychological Corp, 1996
 
Radloff  LS:  The CES-D Scale: a self-report depression scale for research in the general population.  J Applied Psychol Measurement 1977; 1:385–401
[CrossRef]
 
Spielberger  CD:  State-Trait Anxiety Inventory .  Palo Alto, Calif,  Consulting Psychologists Press, 1985
 
Costa  PT  Jr;  McCrae  RR:  NEO PI-R Professional Manual .  Odessa, Fla,  Psychological Assessment Resources, 1992
 
Bernstein  DP;  Fink  L:  Childhood Trauma Questionnaire: A Retrospective Self-Report (CTQ) .  San Antonio, Tex,  Harcourt Assessment, 1997
 
Hamilton  M:  A rating scale for depression.  J Neurol Neurosurg Psychiatry 1960; 23:56–62
[CrossRef] | [PubMed]
 
Bhagwagar  Z;  Wylezinska  M;  Taylor  M;  Jezzard  P;  Matthews  PM;  Cowen  PJ:  Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor.  Am J Psychiatry 2004; 161:368–370
[CrossRef] | [PubMed]
 
Bhagwagar  Z;  Rabiner  EA;  Sargent  PA;  Grasby  PM;  Cowen  PJ:  Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635.  Mol Psychiatry 2004; 9:386–392
[CrossRef] | [PubMed]
 
Bhagwagar  Z;  Hinz  R;  Taylor  M;  Fancy  S;  Cowen  P;  Grasby  P:  Increased 5-HT2A receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [11C]MDL 100,907.  Am J Psychiatry 2006; 163:1580–1587
[CrossRef] | [PubMed]
 
Esterlis  I;  Cosgrove  KP;  Batis  JC;  Bois  F;  Stiklus  SM;  Perkins  E;  Seibyl  JP;  Carson  RE;  Staley  JK:  Quantification of smoking-induced occupancy of beta2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding.  J Nucl Med 2010; 51:1226–1233
[CrossRef] | [PubMed]
 
Staley  JK;  Krishnan-Sarin  S;  Cosgrove  KP;  Krantzler  E;  Frohlich  E;  Perry  E;  Dubin  JA;  Estok  K;  Brenner  E;  Baldwin  RM;  Tamagnan  GD;  Seibyl  JP;  Jatlow  P;  Picciotto  MR;  London  ED;  O'Malley  S;  van Dyck  CH:  Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers.  J Neurosci 2006; 26:8707–8714
[CrossRef] | [PubMed]
 
Zoghbi  SS;  Tamagnan  G;  Baldwin  MF;  Al-Tikriti  MS;  Amici  L;  Seibyl  JP;  Innis  RB:  Measurement of plasma metabolites of (S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates.  Nucl Med Biol 2001; 28:91–96
[CrossRef] | [PubMed]
 
Cosgrove  KP;  Mitsis  EM;  Bois  F;  Frohlich  E;  Tamagnan  GD;  Krantzler  E;  Perry  E;  Maciejewski  PK;  Epperson  CN;  Allen  S;  O'Malley  S;  Mazure  CM;  Seibyl  JP;  van Dyck  CH;  Staley  JK:  123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual phase.  J Nucl Med 2007; 48:1633–1640
[CrossRef] | [PubMed]
 
Bora  E;  Fornito  A;  Pantelis  C;  Yücel  M:  Gray matter abnormalities in major depressive disorder: a meta-analysis of voxel based morphometry studies.  J Affect Disord 2012; 138:9–18
[CrossRef] | [PubMed]
 
van Tol  MJ;  van der Wee  NJ;  van den Heuvel  OA;  Nielen  MM;  Demenescu  LR;  Aleman  A;  Renken  R;  van Buchem  MA;  Zitman  FG;  Veltman  DJ:  Regional brain volume in depression and anxiety disorders.  Arch Gen Psychiatry 2010; 67:1002–1011
[CrossRef] | [PubMed]
 
Ashburner  J;  Friston  KJ:  Unified segmentation.  Neuroimage 2005; 26:839–851
[CrossRef] | [PubMed]
 
Stan  AD;  Ghose  S;  Gao  XM;  Roberts  RC;  Lewis-Amezcua  K;  Hatanpaa  KJ;  Tamminga  CA:  Human postmortem tissue: what quality markers matter? Brain Res 2006; 1123:1–11
[CrossRef] | [PubMed]
 
Bhagwagar  Z;  Murthy  N;  Selvaraj  S;  Hinz  R;  Taylor  M;  Fancy  S;  Grasby  P;  Cowen  P:  5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB.  Am J Psychiatry 2007; 164:1858–1865
[CrossRef] | [PubMed]
 
Bhagwagar  Z;  Wylezinska  M;  Jezzard  P;  Evans  J;  Boorman  E;  Matthews  PM;  Cowen  PJ:  Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients.  Int J Neuropsychopharmacol 2008; 11:255–260
[CrossRef] | [PubMed]
 
Gotti  C;  Moretti  M;  Bohr  I;  Ziabreva  I;  Vailati  S;  Longhi  R;  Riganti  L;  Gaimarri  A;  McKeith  IG;  Perry  RH;  Aarsland  D;  Larsen  JP;  Sher  E;  Beattie  R;  Clementi  F;  Court  JA:  Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation.  Neurobiol Dis 2006; 23:481–489
[CrossRef] | [PubMed]
 
Cosgrove  KP;  Batis  J;  Bois  F;  Maciejewski  PK;  Esterlis  I;  Kloczynski  T;  Stiklus  S;  Krishnan-Sarin  S;  O'Malley  S;  Perry  E;  Tamagnan  G;  Seibyl  JP;  Staley  JK:  Beta2-nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking.  Arch Gen Psychiatry 2009; 66:666–676
[CrossRef] | [PubMed]
 
Heim  C;  Newport  DJ;  Mletzko  T;  Miller  AH;  Nemeroff  CB:  The link between childhood trauma and depression: insights from HPA axis studies in humans.  Psychoneuroendocrinology 2008; 33:693–710
[CrossRef] | [PubMed]
 
Mukhin  AG;  Kimes  AS;  Chefer  SI;  Matochik  JA;  Contoreggi  CS;  Horti  AG;  Vaupel  DB;  Pavlova  O;  Stein  EA:  Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380.  J Nucl Med 2008; 49:1628–1635
[CrossRef] | [PubMed]
 
Shytle  R;  Sheehan  D;  Sanberg  P;  Arias  H:  Neuronal nicotinic receptors as therapeutic targets for mood disorders, in  Pharmacology of Nicotinic Acetylcholine Receptors From the Basic and Therapeutic Perspectives . Edited by Arias  H.  Trivandrum, Kerala, India,  Research Signpost, 2011, pp 187–198
 
References Container

FIGURE 1. 

Regional Availability of β2*-Nicotinic Acetylcholinergic Receptors (β2*-nAChRs) in Acutely Ill and Recovered Patients With Major Depressive Disorder and Matched Healthy Comparison Subjectsa

a Matched on age and gender.

b Determined by VT/fp, where VT is the volume of distribution and fp is the free plasma fraction. Values are means and standard deviations.

Anchor for Jump
TABLE 1.

Radiochemical Measures for [123I]5-I-A-85380 SPECT Imaging of Acutely Ill and Recovered Patients With Major Depressive Disorder and Matched Healthy Comparison Subjectsa

Table Footer Note

a Matched on age and gender.

Table Footer Note

b Hours of infusion equivalent to bolus dose.

Anchor for Jump
TABLE 2.

Demographic and Clinical Characteristics of Acutely Ill and Recovered Patients With Major Depressive Disorder and Matched Healthy Comparison Subjectsa

Table Footer Note

a Matched on age and gender.

Table Footer Note

b Subjects with episodic illness were included.

Table Footer Note

c Scores of the comparison subjects for the acutely ill group are based on only two subjects. Scores of the comparison subjects for the recovered group are based on six subjects.

Table Footer Note

d Scores are based on five acutely ill patients and two of their respective comparison subjects and on 12 recovered patients and six of their respective comparison subjects.

+

References

Shytle  RD;  Silver  AA;  Lukas  RJ;  Newman  MB;  Sheehan  DV;  Sanberg  PR:  Nicotinic acetylcholine receptors as targets for antidepressants.  Mol Psychiatry 2002; 7:525–535
[CrossRef] | [PubMed]
 
Owens  MJ;  Overstreet  DH;  Knight  DL;  Rezvani  AH;  Ritchie  JC;  Bissette  G;  Janowsky  DS;  Nemeroff  CB:  Alterations in the hypothalamic-pituitary-adrenal axis in a proposed animal model of depression with genetic muscarinic supersensitivity.  Neuropsychopharmacology 1991; 4:87–93
[PubMed]
 
Dilsaver  SC:  Pathophysiology of “cholinoceptor supersensitivity” in affective disorders.  Biol Psychiatry 1986; 21:813–829
[CrossRef] | [PubMed]
 
Janowsky  DS;  el-Yousef  MK;  Davis  JM;  Sekerke  HJ:  A cholinergic-adrenergic hypothesis of mania and depression.  Lancet 1972; 2:632–635
[CrossRef] | [PubMed]
 
Risch  SC;  Cohen  RM;  Janowsky  DS;  Kalin  NH;  Murphy  DL:  Mood and behavioral effects of physostigmine on humans are accompanied by elevations in plasma beta-endorphin and cortisol.  Science 1980; 209:1545–1546
[CrossRef] | [PubMed]
 
Janowsky  DS;  Overstreet  DH:  Cholinergic dysfunction in depression.  Pharmacol Toxicol 1990; 66(suppl 3):100–111
[CrossRef] | [PubMed]
 
Zimmerman  M;  Chelminski  I;  McDermut  W:  Major depressive disorder and axis I diagnostic comorbidity.  J Clin Psychiatry 2002; 63:187–193
[CrossRef] | [PubMed]
 
Hughes  JR;  Hatsukami  DK;  Mitchell  JE;  Dahlgren  LA:  Prevalence of smoking among psychiatric outpatients.  Am J Psychiatry 1986; 143:993–997
[PubMed]
 
Poirier  MF;  Canceil  O;  Bayle  F;  Millet  B;  Bourdel  MC;  Moatti  C;  Olie  JP;  Attar-Levy  D:  Prevalence of smoking in psychiatric patients.  Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:529–537
[CrossRef] | [PubMed]
 
Glassman  AH:  Cigarette smoking: implications for psychiatric illness.  Am J Psychiatry 1993; 150:546–553
[PubMed]
 
Breslau  N;  Kilbey  MM;  Andreski  P:  Nicotine dependence and major depression: new evidence from a prospective investigation.  Arch Gen Psychiatry 1993; 50:31–35
[CrossRef] | [PubMed]
 
Quattrocki  E;  Baird  A;  Yurgelun-Todd  D:  Biological aspects of the link between smoking and depression.  Harv Rev Psychiatry 2000; 8:99–110
[PubMed]
 
Grant  BF;  Hasin  DS;  Chou  SP;  Stinson  FS;  Dawson  DA:  Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions.  Arch Gen Psychiatry 2004; 61:1107–1115
[CrossRef] | [PubMed]
 
Tizabi  Y;  Overstreet  DH;  Rezvani  AH;  Louis  VA;  Clark  E  Jr;  Janowsky  DS;  Kling  MA:  Antidepressant effects of nicotine in an animal model of depression.  Psychopharmacology (Berl) 1999; 142:193–199
[CrossRef] | [PubMed]
 
Rabenstein  RL;  Caldarone  BJ;  Picciotto  MR:  The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice.  Psychopharmacology (Berl) 2006; 189:395–401
[CrossRef] | [PubMed]
 
Mineur  YS;  Somenzi  O;  Picciotto  MR:  Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice.  Neuropharmacology 2007; 52:1256–1262
[CrossRef] | [PubMed]
 
Rollema  H;  Guanowsky  V;  Mineur  YS;  Shrikhande  A;  Coe  JW;  Seymour  PA;  Picciotto  MR:  Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect.  Eur J Pharmacol 2009; 605:114–116
[CrossRef] | [PubMed]
 
Caldarone  BJ;  Harrist  A;  Cleary  MA;  Beech  RD;  King  SL;  Picciotto  MR:  High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation.  Biol Psychiatry 2004; 56:657–664
[CrossRef] | [PubMed]
 
Salin-Pascual  RJ;  de la Fuente  JR;  Galicia-Polo  L;  Drucker-Colin  R:  Effects of transdermal nicotine on mood and sleep in nonsmoking major depressed patients.  Psychopharmacology (Berl) 1995; 121:476–479
[CrossRef] | [PubMed]
 
McClernon  FJ;  Hiott  FB;  Westman  EC;  Rose  JE;  Levin  ED:  Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial.  Psychopharmacology (Berl) 2006; 189:125–133
[CrossRef] | [PubMed]
 
George  TP;  Sacco  KA;  Vessicchio  JC;  Weinberger  AH;  Shytle  RD:  Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study.  J Clin Psychopharmacol 2008; 28:340–344
[CrossRef] | [PubMed]
 
Patterson  F;  Jepson  C;  Strasser  AA;  Loughead  J;  Perkins  KA;  Gur  RC;  Frey  JM;  Siegel  S;  Lerman  C:  Varenicline improves mood and cognition during smoking abstinence.  Biol Psychiatry 2009; 65:144–149
[CrossRef] | [PubMed]
 
Musachio  JL;  Villemagne  VL;  Scheffel  UA;  Dannals  RF;  Dogan  AS;  Yokoi  F;  Wong  DF:  Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon.  Nucl Med Biol 1999; 26:201–207
[CrossRef] | [PubMed]
 
Fujita  M;  Tamagnan  G;  Zoghbi  SS;  Al-Tikriti  MS;  Baldwin  RM;  Seibyl  JP;  Innis  RB:  Measurement of alpha4beta2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT.  J Nucl Med 2000; 41:1552–1560
[PubMed]
 
Staley  JK;  van Dyck  CH;  Weinzimmer  D;  Brenner  E;  Baldwin  RM;  Tamagnan  GD;  Riccardi  P;  Mitsis  E;  Seibyl  JP:  123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility.  J Nucl Med 2005; 46:1466–1472
[PubMed]
 
Bhagwagar  Z;  Cowen  PJ:  'It's not over when it's over': persistent neurobiological abnormalities in recovered depressed patients.  Psychol Med 2008; 38:307–313
[CrossRef] | [PubMed]
 
Fujita  M;  Al-Tikriti  MS;  Tamagnan  G;  Zoghbi  SS;  Bozkurt  A;  Baldwin  RM;  Innis  RB:  Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5-I-A-85380.  Synapse 2003; 48:116–122
[CrossRef] | [PubMed]
 
First  MB;  Spitzer  RL;  Gibbon  M;  Williams  JBW:  Structured Clinical Interview for DSM-IV Axis I Disorders—Clinician Version (SCID-CV) .  Washington, DC,  American Psychiatric Press, 1997
 
Beck  AT;  Steer  RA;  Brown  GK:  Beck Depression Inventory, 2nd ed, Manual .  San Antonio, Tex,  Psychological Corp, 1996
 
Radloff  LS:  The CES-D Scale: a self-report depression scale for research in the general population.  J Applied Psychol Measurement 1977; 1:385–401
[CrossRef]
 
Spielberger  CD:  State-Trait Anxiety Inventory .  Palo Alto, Calif,  Consulting Psychologists Press, 1985
 
Costa  PT  Jr;  McCrae  RR:  NEO PI-R Professional Manual .  Odessa, Fla,  Psychological Assessment Resources, 1992
 
Bernstein  DP;  Fink  L:  Childhood Trauma Questionnaire: A Retrospective Self-Report (CTQ) .  San Antonio, Tex,  Harcourt Assessment, 1997
 
Hamilton  M:  A rating scale for depression.  J Neurol Neurosurg Psychiatry 1960; 23:56–62
[CrossRef] | [PubMed]
 
Bhagwagar  Z;  Wylezinska  M;  Taylor  M;  Jezzard  P;  Matthews  PM;  Cowen  PJ:  Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor.  Am J Psychiatry 2004; 161:368–370
[CrossRef] | [PubMed]
 
Bhagwagar  Z;  Rabiner  EA;  Sargent  PA;  Grasby  PM;  Cowen  PJ:  Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635.  Mol Psychiatry 2004; 9:386–392
[CrossRef] | [PubMed]
 
Bhagwagar  Z;  Hinz  R;  Taylor  M;  Fancy  S;  Cowen  P;  Grasby  P:  Increased 5-HT2A receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [11C]MDL 100,907.  Am J Psychiatry 2006; 163:1580–1587
[CrossRef] | [PubMed]
 
Esterlis  I;  Cosgrove  KP;  Batis  JC;  Bois  F;  Stiklus  SM;  Perkins  E;  Seibyl  JP;  Carson  RE;  Staley  JK:  Quantification of smoking-induced occupancy of beta2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding.  J Nucl Med 2010; 51:1226–1233
[CrossRef] | [PubMed]
 
Staley  JK;  Krishnan-Sarin  S;  Cosgrove  KP;  Krantzler  E;  Frohlich  E;  Perry  E;  Dubin  JA;  Estok  K;  Brenner  E;  Baldwin  RM;  Tamagnan  GD;  Seibyl  JP;  Jatlow  P;  Picciotto  MR;  London  ED;  O'Malley  S;  van Dyck  CH:  Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers.  J Neurosci 2006; 26:8707–8714
[CrossRef] | [PubMed]
 
Zoghbi  SS;  Tamagnan  G;  Baldwin  MF;  Al-Tikriti  MS;  Amici  L;  Seibyl  JP;  Innis  RB:  Measurement of plasma metabolites of (S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates.  Nucl Med Biol 2001; 28:91–96
[CrossRef] | [PubMed]
 
Cosgrove  KP;  Mitsis  EM;  Bois  F;  Frohlich  E;  Tamagnan  GD;  Krantzler  E;  Perry  E;  Maciejewski  PK;  Epperson  CN;  Allen  S;  O'Malley  S;  Mazure  CM;  Seibyl  JP;  van Dyck  CH;  Staley  JK:  123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual phase.  J Nucl Med 2007; 48:1633–1640
[CrossRef] | [PubMed]
 
Bora  E;  Fornito  A;  Pantelis  C;  Yücel  M:  Gray matter abnormalities in major depressive disorder: a meta-analysis of voxel based morphometry studies.  J Affect Disord 2012; 138:9–18
[CrossRef] | [PubMed]
 
van Tol  MJ;  van der Wee  NJ;  van den Heuvel  OA;  Nielen  MM;  Demenescu  LR;  Aleman  A;  Renken  R;  van Buchem  MA;  Zitman  FG;  Veltman  DJ:  Regional brain volume in depression and anxiety disorders.  Arch Gen Psychiatry 2010; 67:1002–1011
[CrossRef] | [PubMed]
 
Ashburner  J;  Friston  KJ:  Unified segmentation.  Neuroimage 2005; 26:839–851
[CrossRef] | [PubMed]
 
Stan  AD;  Ghose  S;  Gao  XM;  Roberts  RC;  Lewis-Amezcua  K;  Hatanpaa  KJ;  Tamminga  CA:  Human postmortem tissue: what quality markers matter? Brain Res 2006; 1123:1–11
[CrossRef] | [PubMed]
 
Bhagwagar  Z;  Murthy  N;  Selvaraj  S;  Hinz  R;  Taylor  M;  Fancy  S;  Grasby  P;  Cowen  P:  5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB.  Am J Psychiatry 2007; 164:1858–1865
[CrossRef] | [PubMed]
 
Bhagwagar  Z;  Wylezinska  M;  Jezzard  P;  Evans  J;  Boorman  E;  Matthews  PM;  Cowen  PJ:  Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients.  Int J Neuropsychopharmacol 2008; 11:255–260
[CrossRef] | [PubMed]
 
Gotti  C;  Moretti  M;  Bohr  I;  Ziabreva  I;  Vailati  S;  Longhi  R;  Riganti  L;  Gaimarri  A;  McKeith  IG;  Perry  RH;  Aarsland  D;  Larsen  JP;  Sher  E;  Beattie  R;  Clementi  F;  Court  JA:  Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation.  Neurobiol Dis 2006; 23:481–489
[CrossRef] | [PubMed]
 
Cosgrove  KP;  Batis  J;  Bois  F;  Maciejewski  PK;  Esterlis  I;  Kloczynski  T;  Stiklus  S;  Krishnan-Sarin  S;  O'Malley  S;  Perry  E;  Tamagnan  G;  Seibyl  JP;  Staley  JK:  Beta2-nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking.  Arch Gen Psychiatry 2009; 66:666–676
[CrossRef] | [PubMed]
 
Heim  C;  Newport  DJ;  Mletzko  T;  Miller  AH;  Nemeroff  CB:  The link between childhood trauma and depression: insights from HPA axis studies in humans.  Psychoneuroendocrinology 2008; 33:693–710
[CrossRef] | [PubMed]
 
Mukhin  AG;  Kimes  AS;  Chefer  SI;  Matochik  JA;  Contoreggi  CS;  Horti  AG;  Vaupel  DB;  Pavlova  O;  Stein  EA:  Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380.  J Nucl Med 2008; 49:1628–1635
[CrossRef] | [PubMed]
 
Shytle  R;  Sheehan  D;  Sanberg  P;  Arias  H:  Neuronal nicotinic receptors as therapeutic targets for mood disorders, in  Pharmacology of Nicotinic Acetylcholine Receptors From the Basic and Therapeutic Perspectives . Edited by Arias  H.  Trivandrum, Kerala, India,  Research Signpost, 2011, pp 187–198
 
References Container
+
+

Self-Assessment Quiz - Expired

Did you know? You can add a subscription now to earn CME Credits!

1.
Mice lacking the β2*-nicotinic acetylcholine receptor subunit have been shown to be insensitive to the antidepressant effects of which of the following?
2.
Which of the following observations from the study is true about β2*-nicotinic receptor availability (5-I-A uptake) in patients with major depression using SPECT?
3.
Which of the neurotransmitter systems considered crucial in the pathophysiology of depression is modulated by nicotinic acetylcholine receptors?
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Web of Science® Times Cited: 14

Related Content
Articles
Books
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 45.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 47.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 44.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 45.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 12.  >
Topic Collections
Psychiatric News
APA Guidelines
PubMed Articles